公开(公告)号：US20200299330A1

公开(公告)日：2020-09-24

申请号：US16858071

申请日：2020-04-24

Applicant: AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION

Inventor： Moon Suk KIM ,  Sang Dun CHOI ,  Seung Hun PARK ,  Masaud SHAH

IPC: C07K7/06 ,  A61P17/02

Abstract: A substance P analog having a progenitor cell or stem cell recruiting activity and a method of recruiting progenitor cells or stem cells using the substance P analog are disclosed. The substance P analog has an effect of recruiting endogenous progenitor cells or stem cells to a wound or disease-occurring site. Thus, the disclosure also describes its use in recruiting progenitor cells or stem cells and a method of regenerating or treating a damaged organ or tissue, or a method of healing a wound.

公开(公告)号：US20240059741A1

公开(公告)日：2024-02-22

申请号：US18269708

申请日：2021-12-24

Applicant: AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION

Inventor： Hyun Goo WOO ,  Masaud SHAH ,  Sung Ung MOON

IPC: C07K14/00 ,  A61P31/14

CPC classification number: C07K14/001 ,  A61P31/14 ,  A61K38/00

Abstract: The present invention relates to a composition for prevention or treatment of SARS-CoV-2 infection. CSNP1, CSNP2, CSNP3, and CSNP4 bind to receptor the binding domain (RBD) of the spike protein of SARS-CoV-2 to inhibit the interaction of the spike protein of SARS-CoV-2 with ACE2, thereby interfering with the mechanism that SARS-CoV-2 enters cells or evades immunity. Thus, a composition comprising CSNP1, CSNP2, CSNP3, or CSNP4 as an active ingredient is provided as a pharmaceutical agent for prevention or treatment of SARS-CoV-2 infection (COVID19).